Overview
Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone
Status:
Completed
Completed
Trial end date:
2009-07-01
2009-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The planned study has two purposes: 1. It is to provide evidence that the administration of a cholinesterase inhibitor will result in an increase of IGF-I (primary variable) and in an increase of the secretion growth hormone (secondary variable) that can be maintained throughout the treatment-period of one year. 2. The study also tests the hypothesis that maintenance of increased blood levels of growth hormone and IGF-I can stop or delay the age-related changes of body composition (secondary variables) .Phase:
N/AAccepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Ludwig Boltzmann GesellschaftTreatments:
Cholinesterase Inhibitors
Donepezil
Hormones
Criteria
Inclusion Criteria:- Aged between 70 and 80 years
Exclusion Criteria:
- Cardiac arrhythmias (sick sinus syndrome, AV block, sino-atrial block),
- Treatment with beta-blockers, NSAIDs or cholinergic agonists,
- Known hypersensitivity to donepezil hydrochloride, piperidine derivatives or to any
excipients used in the formulation,
- Gastric and duodenal ulcer,
- Severe renal and hepatic impairment,
- Urinary congestion (prostatic hypertrophy),
- Obstructive pulmonary disease (bronchial asthma);